Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.
Ferreri AJM, Calimeri T, Ponzoni M, Curnis F, Conte GM, Scarano E, Rrapaj E, De Lorenzo D, Cattaneo D, Fallanca F, Nonis A, Foppoli M, Lopedote P, Citterio G, Politi LS, Sassone M, Angelillo P, Guggiari E, Steffanoni S, Tarantino V, Ciceri F, Bordignon C, Anzalone N, Corti A. Ferreri AJM, et al. Among authors: bordignon c. Blood Adv. 2020 Aug 11;4(15):3648-3658. doi: 10.1182/bloodadvances.2020002270. Blood Adv. 2020. PMID: 32766857 Free PMC article. Clinical Trial.
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.
Ferreri AJM, Calimeri T, Conte GM, Cattaneo D, Fallanca F, Ponzoni M, Scarano E, Curnis F, Nonis A, Lopedote P, Citterio G, Politi LS, Foppoli M, Girlanda S, Sassone M, Perrone S, Cecchetti C, Ciceri F, Bordignon C, Corti A, Anzalone N. Ferreri AJM, et al. Among authors: bordignon c. Blood. 2019 Jul 18;134(3):252-262. doi: 10.1182/blood.2019000633. Epub 2019 May 22. Blood. 2019. PMID: 31118164 Free article. Clinical Trial.
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti A, Caligaris-Cappio F, Del Maschio A, Esposito A, De Cobelli F, Dell'Acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C. Gregorc V, et al. Among authors: bordignon c. Eur J Cancer. 2010 Jan;46(1):198-206. doi: 10.1016/j.ejca.2009.10.005. Eur J Cancer. 2010. PMID: 19900802 Clinical Trial.
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.
Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C. Gregorc V, et al. Among authors: bordignon c. Clin Cancer Res. 2011 Apr 1;17(7):1964-72. doi: 10.1158/1078-0432.CCR-10-1376. Epub 2011 Feb 9. Clin Cancer Res. 2011. PMID: 21307147 Clinical Trial.
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
Gregorc V, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer-Bonte JN, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CM. Gregorc V, et al. Among authors: bordignon c. Br J Cancer. 2009 Jul 21;101(2):219-24. doi: 10.1038/sj.bjc.6605162. Epub 2009 Jun 30. Br J Cancer. 2009. PMID: 19568235 Free PMC article. Clinical Trial.
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.
Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, Gentner B, Gullotta F, Ponzoni M, Bernardi M, Marcatti M, Saudemont A, Bordignon C, Savoldo B, Ciceri F, Naldini L, Dotti G, Bonini C, Bondanza A. Casucci M, et al. Among authors: bordignon c. Blood. 2013 Nov 14;122(20):3461-72. doi: 10.1182/blood-2013-04-493361. Epub 2013 Sep 9. Blood. 2013. PMID: 24016461 Free article.
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients.
Lorusso D, Scambia G, Amadio G, di Legge A, Pietragalla A, De Vincenzo R, Masciullo V, Di Stefano M, Mangili G, Citterio G, Mantori M, Lambiase A, Bordignon C. Lorusso D, et al. Among authors: bordignon c. Br J Cancer. 2012 Jun 26;107(1):37-42. doi: 10.1038/bjc.2012.233. Epub 2012 May 29. Br J Cancer. 2012. PMID: 22644293 Free PMC article. Clinical Trial.
Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation.
Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M, Pescarollo A, Bondanza A, Peccatori J, Rossini S, Magnani Z, Salomoni M, Benati C, Ponzoni M, Callegaro L, Corradini P, Bregni M, Traversari C, Bordignon C. Ciceri F, et al. Among authors: bordignon c. Blood. 2007 Jun 1;109(11):4698-707. doi: 10.1182/blood-2006-05-023416. Epub 2007 Feb 27. Blood. 2007. PMID: 17327416 Free article.
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes.
Bondanza A, Valtolina V, Magnani Z, Ponzoni M, Fleischhauer K, Bonyhadi M, Traversari C, Sanvito F, Toma S, Radrizzani M, La Seta-Catamancio S, Ciceri F, Bordignon C, Bonini C. Bondanza A, et al. Among authors: bordignon c. Blood. 2006 Mar 1;107(5):1828-36. doi: 10.1182/blood-2005-09-3716. Epub 2005 Nov 17. Blood. 2006. PMID: 16293601 Free article.
204 results